Description
N-Acetyl Selank is an N-terminally acetylated analog of Selank — a synthetic heptapeptide originally developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow as a synthetic analog of the natural immunomodulatory peptide tuftsin (a 4-amino-acid fragment of IgG Fc heavy chain, residues 289-292). Selank itself adds a C-terminal Pro-Gly-Pro extension to the tuftsin sequence for peptidase resistance; N-Acetyl Selank further extends plasma stability through N-terminal acetylation, which protects against degradation by aminopeptidases. The compound is studied as a research analog for comparative pharmacology versus standard Selank, with particular focus on extended-half-life peptide engineering and SAR studies of N-terminal modifications in short heptapeptides. N-Acetyl Selank has been investigated in preclinical research literature for tuftsin receptor binding, BDNF gene expression endpoints, GABAergic signaling pathway markers, and comparative peptide stability research. Like Selank, the compound is studied here primarily as a research tool for tuftsin-class peptide pharmacology rather than as a defined receptor agonist.
Benefits (Research Focus)
• Tuftsin receptor pharmacology — studied as a stabilized tuftsin-class analog for receptor binding research
• N-terminal modification SAR — investigated for the effect of N-acetylation on peptide stability and receptor activity
• BDNF pathway research — explored for BDNF gene expression endpoints in neuronal cell research models
• GABAergic signaling research — examined for reported interactions with GABA-A receptor system signaling pathways in research models
• Comparative Selank pharmacology — researched alongside standard Selank for comparative SAR and stability studies
What Researchers Look At
• Tuftsin receptor binding affinity and selectivity profiles
• Plasma half-life and peptidase resistance research compared to standard Selank
• BDNF gene and protein expression in neuronal cell research models
• Comparative pharmacology versus standard Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂)
• N-terminal acetylation effects on receptor binding and signaling cascades
Quick Specs
• Form: Lyophilized white powder
• Net Peptide Content: 12 mg per vial
• Quantity: 1 vial
• Appearance: White to off-white lyophilizate
• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)
• Purity: ≥99% by HPLC
• Identity: MS-verified (per COA)
• Storage: Protect from light
Identity Basics
• Compound: N-Acetyl Selank (NA-Selank)
• Synonyms: NA Selank; Acetyl-Selank; N-Ac-TKPRPGP-NH₂; acetylated tuftsin extended analog
• Class: Synthetic heptapeptide research analog; N-terminally acetylated Selank derivative; tuftsin-class peptide
• Sequence: N-Acetyl-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂ — 7 amino acids with N-acetylation and C-amidation
• Origin: N-acetylated analog of Selank, originally developed at the Institute of Molecular Genetics, Russian Academy of Sciences (Moscow)
• Formula / M.W.: C35H59N11O10, ~793.93 g/mol
• CAS: N/A (research analog — standard Selank CAS is 129954-34-3)
⚠️ Disclaimer
- This product is intended for laboratory research use only.
- Not for human or veterinary use.
- Not approved for diagnostic, therapeutic, or medical applications.
- Handle using appropriate laboratory safety procedures and personal protective equipment.
COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.
Janoshik COA — Third-Party Testing
• N-Acetyl Selank VPeptide Canada — December 8, 2025
• N-Acetyl Selank VPeptide Canada — July 1, 2026 – Batch#NASK06-0410
This product has Sterility Testing
• N-Acetyl Selank VPeptide Canada — July 14, 2026 – Batch#NASK06-0410
